SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Future Cloud
Future Cloud Spółka z Ograniczoną Odpowiedzialnością
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Future Cloud Spółka z Ograniczoną Odpowiedzialnością
Future Cloud Spółka z Ograniczoną Odpowiedzialnością (KRS 0001048488, NIP 8661751055) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. FUTURE CLOUD operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since July 25, 2023.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Founded
July 25, 2023
2 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
50.0 K PLN
96 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
N/A
Registry entries
6
latest: December 12, 2025
No KPI data - financial statements and valuation are unavailable for this company.
Rate business credibility - Future Cloud.
No ratings

News
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.

News
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
FUTURE CLOUD's board has 1 member.
6 historical registry entries for Future Cloud
Identifier change
KI.X NS-REJ.KRS/6591/23/232/NIP
Identifier change
KI.X NS-REJ.KRS/6591/23/232/REGON
Registered office change, Address change, Articles of association amended, Primary PKD code change, Secondary PKD code change
KI.X NS-REJ.KRS/5491/24/63
Change in Section 1 (basic data)
KI.X NS-REJ.KRS/5491/24/63/ADE
Articles of association amended, Secondary PKD code change
WA.XII NS-REJ.KRS/71525/25/289
Latest reporting year
-
Available years
0
Filing entries
0
Competing companies or those operating in the same market segment as Future Cloud (in Warszawa, industry: Research and development).
WARSZAWA· Research and development
Revenue 2024: 2.9 B PLN
WARSZAWA· Research and development
Revenue 2024: 796.1 M PLN
WARSZAWA· Research and development
Revenue 2023: 609.6 M PLN
WARSZAWA· Research and development
Revenue 2024: 579.9 M PLN
WARSZAWA· Research and development
Revenue 2024: 499.5 M PLN
WARSZAWA· Research and development
Revenue 2024: 390.5 M PLN